Virtual Library

Start Your Search

Danielle Potter



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-58 - Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort (ID 14057)

      16:45 - 18:00  |  Author(s): Danielle Potter

      • Abstract
      • Slides

      Background

      To describe the demographics, clinical characteristics and treatment sequencing among a real-world cohort of stage III unresectable non-small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) in the US.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Cancerlinq Discovery Database (CLQ), launched by the American Society of Clinical Oncology (ASCO) in 2016, consists of longitudinal, demographically and geographically diverse data aggregated from oncology practice Electronic Health Record (EHR) databases in the US. This retrospective cohort comprises 324 stage III unresectable NSCLC patients who received concurrent, platinum-based chemoradiation between January 1, 2007 and December 31, 2017 (study period). A patient was considered unresectable if s/he did not have surgery within 6 months of the stage III diagnosis date (study index date). A patient’s follow-up period was defined as the time from study index date until the end of the study period, patient death, or loss to follow up, whichever event occured first.

      4c3880bb027f159e801041b1021e88e8 Result

      The cohort was mostly male, white, with a mean age of 66.86 years at index date. Nearly all patients of the cohort (93.57%) had an initial diagnosis of stage III (75.31% IIIA, 2.78% IIIB); 2.47% had an initial stage I diagnosis and 4.00% had an initial diagnosis of stage II. The most common histology was squamous cell carcinoma (46.61%), followed by adenocarcinoma (41.05%). Curation related to clinical characteristics (eg ECOG status, smoking status and other comorbidities) are ongoing, so they are largely missing at this time. During the mean follow-up time of 26.64 months, the cohort received 1.60 lines of therapy (LOT). The most common treatment sequence during the follow-up period consisted of platinum therapy +CRT (82.72%); almost 10% of patients received platinum therapy +CRT, followed by immuno-oncology (IO) therapy. Approximately 38.30% of patients progressed to line of therapy 2 (LOT2) and 29.84% progressed to line of therapy 3 (LOT3), with nearly 18% of patients receiving IO therapy during LOT2 or LOT3.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This exploratory analysis of a stage III unresectable NSCLC cohort is descriptive in nature and suggests that the CLQ Discovery Database can be used to construct generalizable cancer cohorts. Future analyses will focus on validation of CLQ as a real-world data source, using findings from other retrospective, observational studies conducted by AstraZeneca as a benchmark.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.